DLA Piper advised Cantor Fitzgerald, the dealer manager in connection with an offer to exchange certain outstanding warrants to purchase Class A ordinary shares of Zura Bio Limited, and the related solicitation of consents to certain amendments to the warrant agreement governing such warrants.
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases.
The DLA Piper team was led by partner Stephen Alicanti (New York) and included partners Christopher Mikson and Bill Bartow (both in Philadelphia), Kurtis Weaver (Boston), Brad Rock (San Francisco) and associates Jenna Fontenot (Miami) and Priya Narahari (Philadelphia).
DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
